ABSTRACT
Approaches to deal and understand Autism Spectrum Disorder (ASD) phenotypic heterogeneity, quantitatively and multidimensionally, are in need. Being able to access a specific individual relative to a normative reference ASD sample would provide a severity estimate that takes into account the spectrum variance. We propose such an approach analyzing the principal components of variance observable in a clinical reference sample. Using phenotypic data available in a comprehensive reference sample, the Simons Simplex Collection (n=2744 individuals), we performed Principal Component Analysis (PCA). The PCA considered ASD core-symptoms (accessed by ADI-R), important clinical features (accessed by VABS and CBCL) and IQ. PCA-projected dimensions supported a normative modeling where a multivariate normal distribution was used to calculate percentiles. An additional phenotypically homogeneous sample (ASD, IQ<75, 6-7yr, n=60) is presented as a case study to illustrate the phenotypic heterogeneity assessment and individual placement under the normative modeling approach. Three PCs embedded 72% of the normative sample variance, interpreted based on correlations (>0.50) with clinical features as: Social Functionality (39%), Behavioral Disturbance (18%) and Communication Problems (15%). A Multidimensional Severity Score (MSS) to evaluate new prospective single subjects was developed based on percentiles. Additionally, the disequilibrium among PCA-projected dimensions gave rise to an individualized Imbalance Score (ImS). The approach, named TEAplot, is implemented in user-friendly free software and was illustrated in a homogenous independent sample. Our approach proposes a basis for patient monitoring in clinical practice, guides research sample selection and pushes the field towards personalized precision medicine.
Lay Summary Most families or clinicians already heard the now adage: “If you’ve met one person with autism, you’ve met one person with autism”. The phenotypic heterogeneity presented by the Autism Spectrum Disorders (ASD) is a challenge to research and clinical practice. Here in this work we summon established mathematical tools from the Machine Learning field to help one to organize the principal components of such variability. These mathematical tools were applied to a comprehensive database of autistic individuals’ mensurable profiles (cognitive, emotional, behavioural, and so on) maintained by the Simons Foundation Autism Research Initiative (SFARI). Using this normative model one can quantitatively estimate how a given individual person fits into the whole, as pediatricians often do by evaluating growth charts, a tool we named TEAplot. We made freely available Excel/Libreoffice spreadsheets that calculate our proposed Multidimensional Severity Score in order to effectively engage the research and clinical communities. The TEAplot model is a step towards a personalized precision medicine approach for ASD.
Competing Interest Statement
H. B. and J.J.M. are National Research Council (CNPq) research fellows. S.C.C. has received consulting fees from Pfizer and honoraria for lectures from Lundbeck. The other authors declare no conflict of interest.
Funding Statement
We would like to thank all the PROTEA (Autism Spectrum Disorders Program at the Psychiatric Institute of Hospital das Clinicas), TEAMM, and Mackenzie staff who worked on data collection as well as the participating families and patients. We would like to thank all our sources of funding. Part of this study was supported by the State of Sao Paulo Funding Agency (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo) under a special agreement with the Maria Cecilia Souto Vidigal Foundation (grant number 2012/51584-0). Access to Simons Foundation Autism Research Initiative (SFARI) dataset was granted under the proper SFARI review process and also approved by Hospital das Clinicas da FMUSP Research Ethics Committee (CAPPesq) according to review number 2.647.063 and project CAAE57067016.2.0000.0068, review 1.637.312. The protocol was approved by the Research Ethics Committee of UNIFESP (REC) and registered at CAAE19927213.4.1001.5505. It was also financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil (CAPES), Finance Code 001; and National Program to Support Health Care for Persons with Disabilities (PRONAS). H. B. and J.J.M. are National Research Council (CNPq) research fellows. S.C.C. has received consulting fees from Pfizer and honoraria for lectures from Lundbeck. The other authors declare no conflict of interest.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Access to Simons Foundation Autism Research Initiative (SFARI) dataset was granted under the proper SFARI review process and also approved by Hospital das Clinicas da FMUSP Research Ethics Committee (CAPPesq) according to review number 2.647.063 and project CAAE57067016.2.0000.0068, review 1.637.312. The protocol was approved by the Research Ethics Committee of UNIFESP (REC) and registered at CAAE19927213.4.1001.5505.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Presentation information: This study was presented as an abstract at the International Society for Autism Research (INSAR). Virtual Meeting June 3, 2020.
Data Availability
Data that support the findings of this study are available by request to the Simons Foundation Autism Research Initiative (SFARI). Other data are not publicly available due to restrictions regarding the privacy of research participants.
